Imperial Valley Press

‘Magic mushrooms’ for therapy? Vets help sway conservati­ves

-

SALT LAKE CITY (AP) — Matthew Butler spent 27 years in the Army, but it took a day in jail to convince him his post-traumatic stress disorder was out of control.

The recently retired Green Beret had already tried antidepres­sants, therapy and a support dog. But his arrest for punching a hole in his father’s wall after his family tried to stage an interventi­on in Utah made it clear none of it was working.

“I had a nice house, I had a great job, whatever, but I was unable to sleep, had frequent nightmares, crippling anxiety, avoiding crowds,” he said. “My life was a wreck.”

He eventually found psychedeli­c drugs, and he says they changed his life. “I was able to finally step way back and go, ‘Oh, I see what’s going on here. I get it now,’” said Butler, now 52. Today his run-ins with police have ended, he’s happily married and reconciled with his parents.

Butler, who lives in the Salt Lake City suburbs, is among military veterans in several U.S. states helping to persuade lawmakers to study psychedeli­c mushrooms for therapeuti­c use.

Conservati­ve Utah has become at least the fourth state over the last two years to approve studying the potential medical use of psychedeli­cs, which are still federally illegal. A string of cities have also decriminal­ized so-called magic mushrooms and an explosion of investment money is flowing into the arena.

Experts say the research is promising for treating conditions ranging from PTSD to quitting smoking, but caution some serious risks remain, especially for those with certain mental health conditions.

Oregon is so far the only state to legalize the therapeuti­c use of psilocybin, the psychedeli­c active ingredient in certain mushrooms. But studying them for therapy has made inroads not only in blue states like Hawaii, Connecticu­t and Maryland, but also GOPled Texas, Utah and Oklahoma, which passed a study bill through the state House this year.

The progress stands in contrast to medical marijuana, which Utah lawmakers refused to allow until a ballot measure helped push it through. However, the proposal to study a broad range of psychedeli­c drugs passed easily this year.

Texas has yet to legalize medical marijuana, but former Republican Gov. Rick Perry helped shepherd through a bill last year to use $1.4 million to fund a study of psilocybin for treating PTSD.

“The stigma attached to psilocybin and most psychedeli­cs dates back to the 60s and 70s. It’s been very hard for them to overcome,” said Democratic Rep. Alex Dominguez, who sponsored the bill. “My approach was, ‘Let’s find the group that all sides claim that they are supportive of.’ And that would be veterans.”

He also heard from conservati­ves like Perry who support the use of psilocybin to treat PTSD — and let advocates from that end of the political spectrum take the lead publicly.

Maryland also gave bipartisan approval to spending $1 million this year to fund alternativ­e therapies for veterans, including psychedeli­cs. Democratic sponsor Sen. Sarah Elfreth, whose district includes the U.S. Naval Academy, noted the spike in suicides among veterans.

“I don’t envision the VA acting anytime soon,” she said. “We’re at a true crisis level and it’s time for the states to step up.”

Psilocybin has been de

criminaliz­ed in nearby Washington, D.C., as well as Denver, which decriminal­ized it in 2019, followed by Oakland and Santa Cruz in California, Ann Arbor, Michigan, and Cambridge, Massachuse­tts.

There’s also plenty of venture capital being invested from people who have had positive experience­s and are “highly motivated” to invest in psychedeli­cs as treatment, said John Krystal, the chair of psychiatry at Yale University.

Rhode Island lawmakers are weighing a proposal to decriminal­ize psilocybin this year, and in Colorado there’s an effort to get statewide decriminal­ization on the ballot. But similar measures have stalled in Statehouse­s elsewhere, including California and Maine.

Studying psychedeli­cs, though, has gained more traction. In Oklahoma, a bill from Republican Reps. Daniel Pae and Logan Phillips would legalize research

on psilocybin.

“I believe the research will show that there is a way to use this drug safely and responsibl­y, and it could save the lives of thousands of Oklahomans,” Pae said in a statement. The bill passed the House last month and is now under considerat­ion in the Senate.

It’s a stunning turnaround for a field that captivated researcher­s in the 1950s and 1960s, before mushrooms and LSD became known as recreation­al drugs. They were federally outlawed during the Nixon administra­tion, sending research to a screeching halt.

New studies, though, have indicated psilocybin could be useful in the treatment of everything from major depression to alcoholism, said Ben Lewis, an assistant professor of psychiatry at the University of Utah Huntsman Mental Health Institute.

“People are referring to this current period of time

as the psychedeli­c Renaissanc­e,” he said. Up to 30% of depression sufferers are considered resistant to current treatment, and there have been few recent leaps forward in drug innovation, he added.

The risk of addiction or overdose is considered low with psychedeli­cs, especially under medical supervisio­n, and while some cardiac conditions can present a physical risk, many people’s physical reactions aren’t dangerous.

But there are serious psychologi­cal risks, especially for people with certain forms of mental illness or a family history of conditions like schizophre­nia or bipolar disorder.

“Then there’s a possibilit­y that a high-dose psychedeli­c experience could sort of trigger that and lead to long-lasting mental health issues,” said Albert Garcia- Romeu, an assistant professor at Johns Hopkins University School of

Medicine.

Classic psychedeli­cs include LSD, mescaline, psilocybin and ayahuasca. Plant-based psychedeli­cs have long been used in indigenous cultures around the world.

Today, their therapeuti­c use at Johns Hopkins is carefully monitored, Garcia-Romeu said. Patients are rigorously screened and typically have at least three appointmen­ts: one for preparatio­n, a second to take the drugs and a third to work through the psychedeli­c experience.

For Butler, the 2018 arrest at his parents’ home was a turning point. He started researchin­g new ways to deal with the PTSD he has suffered since deploying six times to Iraq and Afghanista­n and working in counterter­rorism and hostage rescues in Somalia for the U.S. Special Forces before retiring as a lieutenant colonel in 2017.

 ?? AP PHOTO/RICK BOWMER ?? Matthew Butler, who spent 27 years in the Army, holds a 2014 photograph of himself during his last deployment in Kabul Afghanista­n, on March 30 in Sandy, Utah.
AP PHOTO/RICK BOWMER Matthew Butler, who spent 27 years in the Army, holds a 2014 photograph of himself during his last deployment in Kabul Afghanista­n, on March 30 in Sandy, Utah.

Newspapers in English

Newspapers from United States